Company Encyclopedia
View More
name
Ausun Pharm
603229.SH
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications.
3.095 T
603229.SHMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking119/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.96%B
    • Profit Margin24.61%A
    • Gross Margin54.51%B
  • Growth ScoreD
    • Revenue YoY-10.07%D
    • Net Profit YoY-28.23%D
    • Total Assets YoY1.42%C
    • Net Assets YoY2.32%C
  • Cash ScoreD
    • Cash Flow Margin406.37%C
    • OCF YoY-10.07%D
  • Operating ScoreD
    • Turnover0.25D
  • Debt ScoreB
    • Gearing Ratio23.30%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Ausun Pharm: Has repurchased a total of 5.2012 million shares, amounting to 50.006 million yuan

    Ausun Pharm announced that as of October 31, 2025, the company has repurchased a total of 5.2012 million shares, with a total payment of 50.006 million yuan, and the repurchase price ranged from 7.52 yuan/share to 11.39 yuan/share. The repurchase plan was initiated on January 24, 2025, with an expected funding usage of 50 million to 100 million yuan, and the repurchase period will last until January 23, 2026. Due to the annual equity distribution in 2024, the upper limit of the repurchase price will be adjusted to no more than 13.90 yuan/share starting from July 17, 2025

    Zhitong·
    SH
    603229
    +0.10%
    Zhitong·
    SH
    603229
    +0.10%

    Ausun Pharm released its performance for the first three quarters, with a net profit attributable to the parent company of 207 million yuan, a year-on-year decrease of 9.59%

    According to the Zhitong Finance APP, Ausun Pharm disclosed its third-quarter report for 2025. The company achieved revenue of 646 million yuan in the first three quarters, a year-on-year decrease of 6.40%; net profit attributable to the parent company was 207 million yuan, a year-on-year decrease of 9.59%; net profit excluding non-recurring gains and losses was 183 million yuan, a year-on-year decrease of 13.83%; basic earnings per share were 0.25 yuan

    Zhitong·
    SH
    603229
    +0.10%
    Zhitong·
    SH
    603229
    +0.10%

    Ausun Pharm: Imatinib Mesylate Tablets Obtained Drug Registration Certificate

    Ausun Pharm's wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., has obtained the Drug Registration Certificate for Imatinib Mesylate Tablets issued by the National Medical Products Administration. This drug is the world's first molecular targeted therapy for tumors, primarily used to treat chronic myeloid leukemia and malignant gastrointestinal stromal tumors. The active ingredient, Imatinib, is a tyrosine kinase inhibitor that can inhibit the proliferation of abnormal white blood cells

    Zhitong·
    SH
    603229
    +0.10%
    Zhitong·
    SH
    603229
    +0.10%

    Ausun Pharm released its semi-annual performance report, with a net profit attributable to the parent company of 169 million yuan, a year-on-year decrease of 5.83%

    According to the Zhitong Finance APP, Ausun Pharm disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 482 million yuan, a year-on-year decrease of 2.14%; net profit attributable to the parent company was 169 million yuan, a year-on-year decrease of 5.83%; net profit excluding non-recurring gains and losses was 151 million yuan, a year-on-year decrease of 12.29%; basic earnings per share were 0.20 yuan

    Zhitong·
    SH
    603229
    +0.10%
    Zhitong·
    SH
    603229
    +0.10%

    Innovative drug concept stocks collectively declined, Ausun Pharm hit the limit down

    Innovative drug concept stocks collectively fell, Ausun Pharm hit the limit down, SDKX dropped over 10%, Thalys, DEZHAN HEALTHCARE, and Hinova had significant declines

    Zhitong·
    SZ
    000813
    -1.75%
    SH
    688302
    -1.91%
    SH
    603229
    +0.10%
    Zhitong·
    SZ
    000813
    -1.75%
    SH
    688302
    -1.91%
    SH
    603229
    +0.10%
    © 2025 Longbridge｜Disclaimer